Filing Details
- Accession Number:
- 0001179110-17-008065
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-05-26 15:10:52
- Reporting Period:
- 2017-05-25
- Filing Date:
- 2017-05-26
- Accepted Time:
- 2017-05-26 15:10:52
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1371217 | Enteromedics Inc | ETRM | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1110780 | Carl Goldfischer | 2800 Patton Road St. Paul MN 55113 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-05-25 | 4,571 | $4.85 | 0 | No | 4 | S | Indirect | See footnote (1) |
| Common Stock | Acquisiton | 2017-05-25 | 97 | $4.85 | 0 | No | 4 | S | Indirect | See footnote note (2) |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | See footnote (1) |
| No | 4 | S | Indirect | See footnote note (2) |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | Director Option (Right to Buy) | $50,410.50 | 2008-03-25 | 2018-03-24 | 3 | 3 | Direct |
| Common Stock | Director Option (Right to Buy) | $12,159.00 | 2009-05-05 | 2019-05-05 | 1 | 1 | Direct |
| Common Stock | Director Option (Right to Buy) | $2,646.00 | 2010-05-06 | 2020-05-06 | 1 | 1 | Direct |
| Common Stock | Director Option (Right to Buy) | $2,761.50 | 2011-05-05 | 2021-05-05 | 9 | 9 | Direct |
| Common Stock | Director Option (Right to Buy) | $2,908.50 | 2012-05-09 | 2022-05-09 | 9 | 9 | Direct |
| Common Stock | Director Option (Right to Buy) | $924.00 | 2013-05-08 | 2023-05-08 | 9 | 9 | Direct |
| Common Stock | Director Option (Right to Buy) | $1,932.00 | 2014-05-07 | 2024-05-07 | 23 | 23 | Direct |
| Common Stock | Director Option (Right to Buy) | $1,176.00 | 2015-05-06 | 2025-05-06 | 23 | 23 | Direct |
| Common Stock | Director Option (Right to Buy) | $1,176.00 | 2015-06-06 | 2025-05-06 | 23 | 23 | Direct |
| Common Stock | Director Option (Right to Buy) | $52.50 | 2016-05-04 | 2026-05-04 | 42 | 42 | Direct |
| Common Stock | Director Option (Right to Buy) | $7.12 | 2017-02-08 | 2027-02-08 | 35,000 | 35,000 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2018-03-24 | 3 | 3 | Direct |
| 2019-05-05 | 1 | 1 | Direct |
| 2020-05-06 | 1 | 1 | Direct |
| 2021-05-05 | 9 | 9 | Direct |
| 2022-05-09 | 9 | 9 | Direct |
| 2023-05-08 | 9 | 9 | Direct |
| 2024-05-07 | 23 | 23 | Direct |
| 2025-05-06 | 23 | 23 | Direct |
| 2025-05-06 | 23 | 23 | Direct |
| 2026-05-04 | 42 | 42 | Direct |
| 2027-02-08 | 35,000 | 35,000 | Direct |
Footnotes
- Represents shares held by Bay City Capital Fund IV, L.P. ("Fund IV"), including the shares held by Dr. Goldfischer; and indirect interests of Bay City Capital LLC ("BCC"), the manager of Bay City Capital Management IV LLC ("Management IV"), and Management IV, the general partner of Fund IV. Dr. Goldfischer is Managing Director of BCC. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein.
- Represents shares held by Bay City Capital Fund IV Co-Investment Fund, L.P. ("Co-Investment IV"), including the shares held by Dr. Goldfischer; and indirect interests of BCC, the manager of Management IV, and Management IV, the general partner of Co-Investment IV. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein.
- 25% of the shares shall vest immediately, and the remaining shares shall vest 1/36 per month thereafter, as long as the reporting person remains a director of the company.
- 25% of the shares subject to the option are exercisable immediately. The remaining 75% of the shares subject to the option shall vest in a series of thirty-six (36) successive equal monthly installments upon completion of each month over the three (3) year period measured from the date shown.
- Option vests in successive installments of 1/12th per month beginning the date shown.
- The price reported is the weighted average sale price for the transactions reported. The prices received ranged from $4.75 to $5.00. The Reporting Person will provide to the issuer, a security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range.
Billionaire Hedge Funds
